New Discovery Brings Lung Regeneration Closer To Reality

Posted on December 29th, 2011 by admin

Article Date: 31 Oct 2011 – 1:00 PDT

Researchers at Weill Cornell Medical College say they have taken an
important step forward in their quest to “turn on” lung regeneration — an
advance that could effectively treat millions of people suffering from
respiratory disorders.
In the journal Cell, the research team reports that they have uncovered
the biochemical signals in mice that trigger generation of new lung
alveoli, the numerous, tiny, grape-like sacs within the lung where oxygen
exchange takes place. Specifically, the regenerative signals originate
from the specialized endothelial cells that line the interior of blood
vessels in the lung.
While it has long been known that mice can regenerate and expand the
capacity of one lung if the other is missing, this study now identifies
molecular triggers behind this process, and the researchers believe these
findings are relevant to humans.
“Several adult human organs have the potential upon injury to regenerate
to a degree, and while we can readily monitor the pathways involved in the
regeneration of liver and bone marrow, it is much more cumbersome to study
the regeneration of other adult organs, such as the lung and heart,” says
the study’s lead investigator, Dr. Shahin Rafii, who is the Arthur B.
Belfer Professor of Genetic Medicine and co-director of the Ansary Stem
Cell Institute at Weill Cornell Medical College.
“It is speculated, but not proven, that humans have the potential to
regenerate their lung alveoli until they can’t anymore, due to smoking,
cancer or other extensive chronic damage,” says Dr. Rafii, who is also an
investigator at the Howard Hughes Medical Institute. “Our hope is to take
these findings into the clinic and see if we can induce lung regeneration
in patients who need it, such as those with chronic obstructive pulmonary
disease (COPD).”
“There is no effective therapy for patients diagnosed with COPD. Based on
this study, I envision a day when patients with COPD and other chronic
lung diseases may benefit from treatment with factors derived from lung
blood vessels that induce lung regeneration,” states Dr. Ronald G.
Crystal, who is a co-author of this study and professor of pulmonary and
genetic medicine at Weill Cornell.
Dr. Rafii and his researchers had previously uncovered growth factors that
control regeneration in the liver and bone marrow, and in both cases, they
found that endothelial cells produce the key inductive growth factors,
which they defined as “angiocrine factors.” In the current lung study,
they discovered the same phenomenon — that blood vessel cells in the
lungs jump-start regeneration of alveoli. “Blood vessels are not just the
inert plumbing that carries blood. They actively instruct organ
regeneration,” says Dr. Rafii. “This is a critical finding. Each organ
uses different growth factors within its local vascular system to promote
regeneration.”
To conduct this study, Dr. Bi-Sen Ding, a postdoctoral fellow in Dr.
Rafii’s lab and the first author of this paper, removed the left lungs of
mice and studied the biochemical process of subsequent regeneration of the
remaining right lung. Previous pioneering work by Dr. Crystal had shown
that when the left lung of mice is removed, the right lung regenerates by
80 percent, effectively replacing most of the lost alveoli. “This
regeneration process also restores the physiological respiratory function
of the lungs, which is mediated by amplification of various epithelial
progenitor cells and regeneration of the alveolar sacs,” says Dr. Ding.
“This regenerative phenomenon, however, only occurs after a trauma that
abruptly reduces lung mass. Then the specific subsets of blood vessels in
the remaining lung receive a message to start to repopulate alveoli, and
our job was to find that signal,” says Dr. Daniel Nolan, a senior
scientist in this project who developed methods to characterize the lung
blood vessel cells.
The scientists found that removal of the left lung activates receptors on
lung endothelial cells that respond to vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (FGF-2). Activation of these
receptors promotes the rise of another protein, matrix
metalloproteinase-14 (MMP14). The researchers discovered that MMP14, by
releasing epidermal growth factors (EGF), initiates the generation of new
lung tissue.
When the investigators disabled receptors of VEGF and FGF-2 specifically
in the endothelial cells of the mice, the right lung would not regenerate.
The defect in the lung regeneration was found to be due to the lack of
MMP14 generation from the blood vessels. Remarkably, when these mice
received an endothelial cell transplant from a normal mouse, the
production of MMP14 was restored, triggering the regeneration of
functional alveoli.
“The recovery of lung function and lung mechanics by transplantation of
endothelial cells that stimulate MMP14 production may be valuable for
designing novel therapies for respiratory disorders,” says Dr. Stefan
Worgall, who helped with the functional lung studies in this project.
“This study will also help us understand mechanisms for repair in the
growing lungs of infants and children,” he adds. Dr. Worgall is associate
professor of pediatrics and genetic medicine and distinguished associate
professor of pediatric pulmonology.
Given MMP14′s role, Dr. Rafii classifies it as a crucial “angiocrine”
signal — a lung endothelial specific growth factor responsible for
alveolar regeneration. Dr. Rafii’s team also seeks to reveal the
initiation signals resulting in the activation of lung blood vessels.
“Changes in local blood flow and biomechanical forces in the remaining
lung after removal of the left lung could certainly be one of the
initiation cues that induce endothelial activation,” says Dr. Sina
Rabbany, who is a co-senior author of this study and a professor of
bioengineering at Hofstra University and adjunct associate professor of
genetic medicine and bioengineering in medicine at Weill Cornell.
The researchers will next determine if MMP14 and other as-yet unrecognized
angiocrine factors are responsible for lung regeneration in humans as well
as mice. “We believe the same process goes on in humans, although we have
no direct evidence yet,” says Dr. Ding. The study’s authors theorize that
patients with COPD (a disorder most often caused by chronic smoking) have
so much damage to their lung endothelial cells that they no longer produce
the proper inductive signals. “We know
smoking damages lungs, but lungs may continue to regenerate alveoli,” says
Dr. Koji Shido, a co-author of this study. “But at certain point,
significant injury to the endothelial cells could impair their capacity to
support lung regeneration.”
“Perhaps replacement of angiocrine factors, or transplantation of normal
lung endothelial cells derived from pluripotent stem cells, could restore
lung regeneration” speculates Dr. Zev Rosenwaks, who is the director of
the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine
at Weill Cornell, and a co-author of this study. “Currently, we are
generating pluripotent stem cells derived from patients with genetic
pulmonary disorders to identify potential pathways, which may ultimately
enhance our understanding of how lung endothelial cells may improve lung
function in these patients.”

http://www.medicalnewstoday.com/releases/236793.php

WISE Study for sarcoidosis

Posted on December 28th, 2011 by admin
WISE, an online survey for individuals affected
by sarcoidosis, is being conducted by investigators at
The University of Iowa to better understand the disease
and its impact on a global scale.

If you are living with sarcoidosis, or know somebody who does, we urge you to share 

your experience with us. Please register by visiting
www.sarcoidstudy.org today.
Once registered, you may fill out the online
questionnaires at your convenience.

Asthma and EPA

Posted on December 27th, 2011 by admin

Statement of Bill McLin, President and CEO, Asthma and Allergy Foundation of America (AAFA) Commending the Environmental Protection Agency for Adopting the Mercury and Air Toxics Standards Rule

December 21, 2011

On behalf of the Asthma and Allergy Foundation of America (AAFA), I commend the United States Environmental Protection Agency (EPA) for its action announced today implementing the Mercury and Air Toxics Standards rule. For the 20 million Americans with asthma – including 6.7 million children for whom breathing without thinking is not so routine and, who are more likely to sleep poorly at night and miss work or school by day – the content of the air they breathe is top of mind. This rule will set the first national safeguard that limits power plant emissions of mercury, arsenic and other toxic substances that burden the health of our children and communities. This new rule will help protect the health of those most at risk: children, teens, seniors, and people with chronic lung diseases like asthma. According to the EPA, the new Mercury and Air Toxics Standards Rule will prevent an estimated 17,000 premature deaths and 11,000 heart attacks, in addition to eliminating 120,000 incidents of asthma symptoms and 11,000 cases of acute bronchitis in children each year.

We recognize that some critics cite adverse economic impacts of tighter standards. However, this new rule will not only avoid lost wages for patients and parents of children with asthma, lost productivity for the companies that employ them, and increased hospital admissions. It will also create 31,000 construction jobs and 9,000 long-term utility jobs while increasing the demand for investments in energy efficiency and clean technology.

The economic burden of asthma and other respiratory diseases, cancers and cardiovascular diseases are borne by taxpayers via Medicare and Medicaid, and are being borne by corporations who employ these Americans, pay the costs of health insurance for them and their children, and lose productivity when they are sick or caring for their chronically ill loved ones.

AAFA believes that this EPA action is the right step to help keep Americans with asthma safe and healthy.

(AAFA is an independent, not-for-profit voluntary health agency dedicated to improving the quality of life for people with asthma and allergies. AAFA was founded in 1953 by the two leading professional medical organizations in the United States devoted to the allergy/immunology specialty.)

Why you need to exercise with lung disease

Posted on May 8th, 2011 by admin

Effects of pulmonary rehabilitation on quality of life in chronic
obstructive pulmonary disease patients.

Moullec G, Laurin C, Lavoie KL, Ninot G.

Montreal Behavioural Medicine Centre, Canada.

Abstract

PURPOSE OF REVIEW:

Pulmonary rehabilitation plays a key role in the management of
chronic obstructive pulmonary disease (COPD). Although the American
Thoracic Society recently provided a grade of 1A for evidence of
health-related quality of life (HRQoL) benefits related to pulmonary
rehabilitation, knowledge about the psychological and behavioral
processes explaining the impact of pulmonary rehabilitation on HRQoL
in COPD patients remains limited. This review describes the state of
knowledge over the past year concerning HRQoL benefits after
pulmonary rehabilitation and suggests avenues for future research.

RECENT FINDINGS:

HRQoL outcomes related to pulmonary rehabilitation explores five
themes: optimizing pulmonary rehabilitation components to improve
HRQoL; characterization of a responder phenotype; suitability of
pulmonary rehabilitation following acute exacerbations; exploration
of psychological and behavioral mechanisms explaining pulmonary
rehabilitation benefits; and long-term maintenance of HRQoL benefits
after pulmonary rehabilitation.

SUMMARY:

Evidence supports the use of pulmonary rehabilitation to improve
HRQoL in patients with moderate-to-severe COPD. However, it is
unclear how pulmonary rehabilitation improves HRQoL and which
characteristics confer the greatest HRQoL benefits. Moreover, most
studies failed to provide a compelling theoretical rationale for the
intervention employed. Future research should focus on improving the
understanding of the psychological mechanisms implicated in the
adoption and maintenance of healthy behavior.

PMID: 21206273

http://www.ncbi.nlm.nih.gov/pubmed/21206273

We have lost one of the world’s greatest teachers, a dear friend.

Posted on April 7th, 2011 by admin

Dec 13 2009

We have lost one of its greatest teachers and friend. It deeply saddens me to write:
Dr. Thomas L. Petty, will be missed by all in the COPD/ Lungworld. Continue reading →

Jan 2010 FAA Guidelines

Posted on April 7th, 2011 by admin

January 6, 2010

The Federal Aviation Administration (FAA) announced today that passengers needing medical oxygen now have the option of using four additional portable oxygen concentrators while traveling, bringing the total number of approved units to 11. Continue reading →

GLOBAL PRIMARY CARE AND PATIENT EDUCATION CLINICAL USE OF PULSE OXIMETRY- Pocket Reference 2010e

Posted on April 7th, 2011 by admin

Helping the World Breathe Free
THE PURPOSE OF THIS GUIDE

Chronic respiratory diseases such as COPD and asthma are among the most common health conditions seen in primary care practices, affecting more than 1 billion patients worldwide. Primary care clinicians Continue reading →

Everything Respiratory Magazine

Posted on April 7th, 2011 by admin

The first magazine created by respiratory consumers, for respiratory consumers.

First Ever 100% Silicon Oxygen Cannula for COPD and Long – -Term Oxygen Patients

Posted on April 7th, 2011 by admin

First commerically available 100% silicon oxygen cannula. Long term oxygen therapy patients now have a new alternative cannula that is non-allergic, soft even in very cold weather, doesn’t stink of plastic, and is guaranteed to last at least one year. Continue reading →

 

Shop these great Respiratory products!

www.ERMAG.org